Browse > Article

Post-marketing Surveillance Study of an Inactivated Split-Virion Influenza Vaccine in Korea  

Huh, Jae-Won (Department of Pediatrics, Il-sin Christian Hospital)
Ma, Sang-Hyuk (Department of Pediatrics, Changwon Fatima Hospital)
Kim, Hyun-Kyun (Mirae Pediatric Hospital)
Gunapalaiah, Bhavyashree (GlaxoSmithKline Biologicals)
Bock, Hans L. (GlaxoSmithKline Biologicals)
on behalf of the Fluarix-054 Study Group, (Members of the Fluarix-054 Study Group are listed at the end of this section)
Publication Information
Pediatric Infection and Vaccine / v.18, no.1, 2011 , pp. 68-79 More about this Journal
Abstract
Purpose : This post-marketing surveillance study (NCT00750360) assessed the safety and reactogenicity of an inactivated, trivalent split-virion influenza vaccine licensed for use in the Korea since 2002. Methods : Eight hundred and eighty three subjects aged 6 months received a single dose of the ${\geq}$ vaccine; an additional dose was administered to those aged <9 years and unprimed with an influenza vaccine. Four hundred and eleven subjects used diary cards to record safety information; this report presents data from these subjects. Incidence of solicited local, general and unsolicited adverse events (4-days and 21-days post-vaccination follow-up periods, respectively) were recorded. Serious adverse events (SAEs) were recorded throughout the study period. Results : Injection site pain (subjects aged <6 years: 12.6% of subjects, ${\geq}$6 years: 34.7%), fever (<6 years: 1.3%) and myalgia (${\geq}$6 years: 13.9%) were the most frequently recorded solicited local and general adverse events. Grade 3 solicited adverse events were reported by ${\leq}$4.0% subjects. No vaccine-related SAEs were recorded (KFDA criteria). Conclusion : Considering the vaccine's well-established immunogenicity and its favourable safety and reactogenicity profile across all age groups and its high coverage rate in Korea, it may be recommended as a candidate to facilitate annual seasonal influenza vaccination for all ages as part of the Korean National Immunization Program.
Keywords
Influenza vaccine; Reactogenicity; Safety;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 World Health Organization (WHO). Position Paper Influenza Vaccines. Wkly Epidemiol Rec 2005;80:277-88.
2 World Health Organization (WHO). Influenza overview. Available: http://www.who.int/mediacentre/factsheets/2003/fs211/en/ Accessed: 18 May 2010.
3 Rose GW, Cooper CL. $Fluarix^{TM}$, inactivated split-virus influenza vaccine. Expert Opin Biol Ther 2006;6:301-10.   DOI   ScienceOn
4 Nichol KL. Efficacy and effectiveness of influenza vaccination. Vaccine 2008;26S:D17-22.
5 Tilburt JC, Mueller PS, Ottenberg AL, Poland GA, Koenig BA. Facing the challenges of influenza in healthcare settings: The ethical rationale for mandatory seasonal influenza vaccination and its implications for future pandemics. Vaccine 2008;26S:D27-30.
6 Fiore AE, Shay DK, Broder K, Iskander JK, Uyeki TM, Mootray G, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Morb Mortal Wkly Rep 2009;58:RR8.
7 Kim SH, Huh JH, Bae SY, Kim JS, Yoon SY, Lim CS, et al. Epidemiology of respiratory viral infection in 2004-2006. Korean J Lab Med 2006;26:351-7.   DOI   ScienceOn
8 Kim MR, Lee HR, Lee GM. Epidemiology of acute viral respiratory tract infections in Korean children. J Infect 2000;41:152-8.   DOI   ScienceOn
9 Kim YK, Nyambat BH, Hong YS, Lee CG, Lee JW, Kilgore PE. Burden of viral respiratory disease hospitalizations among children in a community of Seoul, Republic of Korea, 1995-2005. Scand J Infect Dis 2008;40:946-53.   DOI   ScienceOn
10 Chun BC, Woo HJ, Park SC. Preventive efficacy of influenza vaccination against to influenza-like illness among eldery. Korean J Epidemiol 1999;21:205-19.
11 Lee HJ. Classification of vaccination and immunization schedule recommended by the Korean Pediatric Society, 2008. J Korean Med Assoc. 2008;51:104-9.   DOI   ScienceOn
12 Kee SY, Lee JS, Cheong HJ, Chun BC, Song JY, Choi WS, et al. Influenza vaccine coverage rates and perceptions on vaccination in South Korea. J Infect 2007;55:273-81.   DOI   ScienceOn
13 The Korean Pediatric Society. [Influenza]. In: Kang JH, ed. Immunization Guideline. 5th ed. Seoul: The Korean Pediatric Society; 2002:[136-54].
14 Seo JJ, Kim MJ, Kim SH, Kee HY, Chung JK, Kim ES, et al. Characterization of respiratory viral infection in children in Gwangju. J Infect and Chemother 2008;40:218-29.   DOI
15 Treanor JJ, Campbell JD, Brady RC, Keitel WA, Drame M, Jain VK, et al. Rapid licensure of a new, inactivated influenza vaccine in the United States. Hum Vaccin 2005;1:239-44.   DOI
16 Lee JS, Shin KC, Na BK, Lee JY, Kang C, Kim JH, et al. Influenza surveillance in Korea: establishment and first results of an epidemiological and virological surveillance scheme. Epidemiol Infect 2007;135:1117-23.
17 Nah SY, Park SE, Park JY, Lee HJ. Epidemiology of influenza virus over 8 years (1990-1998) in Seoul, Korea. Korean J Infect Dis 1999;31:210-6.
18 Glezen WP, Denny FW. Epidemiology of acute lower respiratory disease in children. N Engl J Med 1973;288:498-505.   DOI   ScienceOn
19 Hehme NW, Kunzel W, Petschke F, Turk G, Raderecht C, van Hoecke C, et al. Ten years of experience with the trivalent split-influenza vaccine, $Fluarix^{TM}$. Clin Drug Invest 2002;22:751-69.   DOI   ScienceOn
20 El Sahly HM, Keitel WA. Clinical data on $Fluarix^{TM}$: an inactivated split seasonal influenza vaccine. Expert Rev Vaccines 2008;7:713-9.   DOI   ScienceOn
21 Zaman K, Roy E, Arifeen SE, Rahman M, Raqib R, Wilson E, et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med 2008;359:1555-64.   DOI   ScienceOn
22 Heckler R, Baillot A, Engelmann H, Neumeier E, Windorfer A. Cross-Protection against homologous drift variants of influenza A and B after vaccination with split vaccine. Intervirology 2007;50:58-62.   DOI   ScienceOn